COMPANY PROFILE
YUMAB is a biotechnology company founded in 2012 by experts and pioneers in recombinant antibody technologies of the University of Braunschweig, Germany. Since then, YUMAB has become a world leading provider for the development of fully human, therapeutic antibodies. YUMAB offers outstanding expertise from more than 30 years of continuous research in recombinant antibody technologies in combination with state of the art and next generation technologies. This unique setting enables novel solutions for current and future challenges in antibody immunotherapy.
“Fully human” antibodies reinvented – nature-derived, close to germline
YUMAB, unlike others, follows strictly the rationale to develop “fully human” antibodies from “nature-derived” human antibody sequences and libraries, because each sequence pre-selected in the human body minimizes non-predictable toxicity and immunogenicity and, thus, the risk at later stages in drug development. The very large repertoire of YUMAB® libraries maximizes epitope diversity often repressed during in vivo immunization
Fast translation from research with “drug-like” antibodies
Early on, YUMAB® antibody candidates have “drug-like” properties (recombinant format, fully human, high quality properties by in vitro selection) compared to animal-derived antibodies, which facilitates direct translation from research to drug development. YUMAB® antibodies are already several steps ahead in the value chain, which may also facilitate financing next steps.
Accelerating antibody drug development
The YUMAB® platform provides powerful fully human antibody technologies that accelerate the translation from research to drug development, reducing unnecessary engineering steps like humanization. Thereby, YUMAB supports the current paradigm change in the antibody market away from murine, chimeric and humanized antibodies to fully human antibody drugs.
Universal technology access for tomorrow’s medicines
YUMAB’s philosophy is to make the best technologies available for anyone, who is seriously engaged in antibody drug development including start-ups, biotech or biopharma companies. We also aim to jump-start innovation within the frame of our academic and industrial collaborations. Modern healthcare demands new and better drugs and we aim to drive and bridge innovation.
